Medicine and Health Sciences Commons^™

Impact Of Inhaled Epoprostenol In Patients On Covid-19 Acute Respiratory Distress Syndrome (Ards), Stacey Nguyen, Stephen Chromi, Mark Decerbo, Surajit Dey, Joseph Mccoy, Jeffrey Murawsky

HCA Healthcare Journal of Medicine

Background

Coronavirus disease 2019 (COVID-19), a novel respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can progress to critical illness and the development of acute respiratory distress syndrome (ARDS). Variability in clinical presentation has led to 2 distinct theoretical classifications of COVID-19 ARDS based on different phenotypical presentations. The first of which follows closely to traditional ARDS presenting as severe hypoxemia with markedly reduced lung compliance, whereas the second presents as severe hypoxemia with preserved to high lung compliance. With uncertainty surrounding the specific pathological and mechanistic nature of COVID-19, we designed this study to elucidate the …

Discovery Of Sars-Cov-2 Rna-Dependent-Rna-Polymerase (Rdrp) Inhibitor From Sambiloto (Andrographis Paniculata) Based On Molecular Docking And Admet Prediction Approach, Dina Ahsana, Rizki Rahmadi Pratama, Alfisyahriatunnida Meily, Andika Andika

Pharmaceutical Sciences and Research

The rapid spread of the coronavirus disease 2019 (COVID-19) has led to the development of therapeutic inhibitor drug of SARS-CoV-2, which can inhibit the viral enzyme RNA-dependent-RNA-polymerase (RdRp), thereby preventing the replication, transcription, and synthesis of RNA virus in the host cells. Previous in-vitro studies revealed that Andrographis paniculata has the potential to inhibit the virus. Therefore, this study aims to isolate the specific compounds of Andrographis paniculata, which play a role in inhibiting SARS-CoV-2 RdRp using molecular docking. A total of 19 compounds were identified in previous literature studies, while remdesivir and favipiravir were used as the positive …

Covid-19: The Vaccine Race Continues, L. Hayley Burgess, Carley Castelein, Andrew Rubio, Mandelin K. Cooper

HCA Healthcare Journal of Medicine

Over a year has passed since the discovery of SARS-CoV-2 and the subsequent COVID-19 pandemic. As mitigation efforts continue, COVID-19 has claimed over half a million lives in the United States and 3.1 million lives globally. The development and availability of vaccines delivering immunity to prevent COVID-19 offers hope to end the pandemic.

Emergency use authorizations from the Food and Drug Administration have been issued in the United States for three vaccines, one each from Pfizer-BioNTech, Moderna and Janssen/J&J. Pfizer-BioNTech and Moderna are both mRNA vaccines with efficacy of 95% and 94.1% respectively, while the vector-based vaccine from Janssen/J&J has …

A Data Driven Approach To Profile Potential Sars-Cov-2 Drug Interactions Using Tylerade, Robert P. Schumaker, Michael A. Veronin, Trevor Rohm, Matthew Boyett, Rohit R. Dixit

Journal of International Technology and Information Management

We use a data driven approach on a cleaned adverse drug reaction database to determine the reaction severity of several covid-19 drug combinations currently under investigation. We further examine their safety for vulnerable populations such as individuals 65 years and older. Our key findings include 1. hydroxychloroquine/chloroquine are associated with increased adverse drug event severity versus other drug combinations already not recommended by NIH treatment guidelines, 2. hydroxychloroquine/azithromycin are associated with lower adverse drug event severity among older populations, 3. lopinavir/ritonavir had lower adverse reaction severity among toddlers and 4. the combination of azithromycin, hydroxychloroquine and tocilizumab is safer than …

Covid-19: Race For Vaccine, L. Hayley Burgess, Jason J. Braithwaite, Emily Singleton, Aaron M. Young, Mandelin K. Cooper

HCA Healthcare Journal of Medicine

The world is in the midst of a pandemic from COVID-19, a disease caused by the virus SARS-CoV-2. Despite broad mitigation efforts, new cases continue with 74 million cases and 1.6 million deaths worldwide. Regardless of previous research efforts, there is no commercially available vaccine for any coronavirus. Novel vaccine development has historically taken at least 10 years from discovery to availability with only a 6% market entry probability.

With the global impact, there is an urgency to expedite a vaccine to protect the population. The U.S. government launched Operation Warp Speed with the goal to produce and deliver 300 …

Importance Of Awareness Of Adverse Drug Reaction Reporting During The Covid-19 Pandemic, Heather Ellis, Hale Z. Toklu

HCA Healthcare Journal of Medicine

Health care professionals hold the responsibility of reporting any adverse drug reactions in order to learn about new therapy and how best to safely care for our patients. The information derived from case publications and FDA MedWatch reports are essential to accumulate information and increase awareness for the possible risks of new drugs.

Potential Of Jamu In Nanotechnology Perspective As An Alternative Treatment For Covid-19, Dhadhang Wahyu Kurniawan, Azis Ikhsanudin

Pharmaceutical Sciences and Research

The world seems to be recovering at this time, especially because of the 2019 global coronavirus disease pandemic (COVID-19) caused by the Coronavirus 2 virus (SARS-CoV-2). This virus is similar to other β-coronaviruses through several steps to enter and bind angiotensin-converting enzyme 2 (ACE2) as the main receptor. This binding, particularly in the respiratory epithelium and alveoli of the lungs, affects harmony in human host cells. No specific vaccines and antivirals are available to date as drug investigations are still ongoing. However, many Indonesians consume herbal medicine, especially 'empon-empon' containing the Zingiberaceae family, to protect their health from COVID-19. So …

Remdesivir-Warfarin Interaction: A Case Report, Kayihura Manigaba, Josh Hawks, Marie Kima

HCA Healthcare Journal of Medicine

A greater than 65-year-old Caucasian woman receiving long-term anticoagulation with warfarin for atrial fibrillation experienced a sudden rise in an international normalized ratio (INR) after she was started on remdesivir for management of 2019 Novel Coronavirus (COVID-19). Patient INR was maintained within the target therapeutic range of 2–3 with a warfarin dose of 11 mg/week before starting remdesivir. After 2 days of remdesivir therapy, the patient’s INR increased significantly and remained elevated during the 5 day course of remdesivir therapy. Patient required an interruption of her warfarin therapy for 7 days, and her INR did not return to the targeted …

Pharmacy Services Reboot Roadmap: Resiliency During The Covid-19 Pandemic, L. Hayley Burgess, Joan S. Kramer, Brian Moran, Mandelin Cooper, Christine Dunn, Edward Murray, Karla M. Miller

HCA Healthcare Journal of Medicine

Planning for resumption of patient care services during and following the impact of novel coronavirus disease-2019 (COVID-19) while controlling costs are essential for pharmacy services resiliency. Implementation of a pharmacy services reboot roadmap across a 179 hospital health-system is described. The roadmap encompassed eight key areas: pharmacy leadership, staffing and scheduling, clinical pharmacy services, medication safety, medication supply, regulatory and compliance, team support opportunities, and financial stewardship. A supporting checklist and volume-based staffing plan are included as examples to assist pharmacy leaders in planning optimal pharmacy services support as patient volumes increase, particularly in the emergency department, surgical services and …

Epigenetic Diet To Modulate Immune Response Against Sars-Cov-2, Andika Andika, Risa Ahdyani, Linda Erlina, Azminah Azminah, Arry Yanuar

Pharmaceutical Sciences and Research

The COVID-19 pandemic has spread to various parts of the world and caused many deaths. The victims are infected by SARS-CoV-2, a new type of coronavirus that has appeared since December 2019 and caused respiratory symptoms, fever, coughing, and shortness of breath. In addition to social distancing, wearing masks and washing hands, diet is important as a defense of the body against SARS-CoV-2. In this review, researchers conducted epigenetic diet studies that could potentially inhibit SARS-CoV-2, and can be consumed and used on a daily basis.